|
|
|
Dear [fullname,fallback=Recipient's name],
|
|
Are you interested in learning about the latest innovations in pulmonary arterial hypertension (PAH)? Join us at the ERS International Virtual Congress 2020 for a presentation about our investigational drug candidate, sotatercept.
|
|
On September 8, we are hosting a lunchtime activity session focused on a new potential therapy that may change the course of PAH progression by rebalancing BMPR-II signalling.
|
|
A New Direction in PAH:
|
|
A Potential Therapy for Rebalancing BMPR-II Signalling
|
|
|
|
Featuring Vallerie McLaughlin, MD, University of Michigan, Ann Arbor
|
|
September 8, 2020, 13:15-13:45 Central European Time
|
|
Topic overview
|
|
Despite multiple treatment options, patients with PAH still face a devastating and progressive disease.
This programme will focus on the imbalances in BMPR-II and activin receptor signalling that may drive PAH progression.
A new therapeutic approach that aims to rebalance this signalling will be discussed in the context of potential
disease modification.
|
|
|
|
|
|
On September 8, click the button above 15 minutes before the 13:15 session begins. Please be aware that there is a limit of 50 viewers for this session.
|
|
|
Acceleron is passionate about accelerating the discovery of novel therapies that can help patients with PAH and other rare diseases. We hope you find this presentation helpful as we look to the future of PAH therapy.
|
|
|
Learn more about Acceleron
|
|
In the meantime, you can learn more about us by visiting
|
|
our ERS 2020 industry programme page.
|
|
|
|
If you have any questions about our clinical trials, eligibility, enrolment, or our pulmonary pipeline, feel free to contact us at +1 617-649-9200.
|
|
|
|